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Abstract
Rationale—Bone marrow (BM)-derived mesenchymal stem cells (MSCs) hold great promise for
cardiovascular cell therapy owing to their multipotency and culture-expandability.
Objective—The aim of the study was to investigate whether MSCs can treat experimental acute
myocardial infarction (MI) and diabetic neuropathy.
Methods and Results—We isolated mononuclear cells from mouse BM and cultured MSCs in
a conventional manner. Flow cytometry analyses of these cultured cells at passage four showed
expression of typical MSC markers such as CD44 and CD29, but not hematopoietic markers such
as c-kit, flk1 and CD34. To determine the therapeutic effects of MSCs, we injected MSCs into the
periinfarct area after ligation of the left anterior descending coronary arteries of mice, and as
separate experiments injected the same batch of MSCs into hindlimb muscles of mice with
diabetic neuropathy. During the follow-up at 4–8 weeks after cell transplantation, growing tumors
were observed in 30% of hearts in the MI model, and in 46% of hindlimbs in the diabetic
neuropathy model. Histologic examination of the tumors revealed hypercelluarity, pleomorphic
nucleoli, cytologic atypia and necrosis, and positive staining for α-smooth muscle actin, indicative
of malignant sarcoma with myogenic differentiation. Chromosomal analysis of these MSCs
showed multiple chromosomal aberrations including fusion, fragmentation, and ring formation.
Conclusions—Genetically unmodified MSCs can undergo chromosomal abnormalities even at
early passages and form malignant tumors when transplanted in vivo. These results suggest that
careful monitoring of chromosomal status is warranted when in vitro expanded MSCs are used for
cell therapy such as for MI.
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Introduction
Isolated from various sources including bone marrow (BM), cartilage, adipose tissue,
amniotic fluids and umbilical cord blood,1–3 mesenchymal stem cells (MSCs) have drawn
much attention for cell therapy because they can be easily expanded in vitro and
differentiate into tissues of mesenchymal origin, including muscle, fibroblast, bone, tendon,
ligament, and adipose tissue.4 Indeed, MSCs have been used for regenerating damaged
tissues of noncardiac disorders such as stroke, Crohn’s disease, osteogenesis imperfecta, and
graft versus host disease.5–8 Furthermore, MSCs have been used to regenerate
cardiovascular tissues by virtue of their capability to transdifferentiate into cardiomyocytes
and vessel-like cells.9–16 One pilot study reported that intracoronary injection of autologous
MSCs could improve global and regional LV function and reduce the size of the perfusion
defect in patients with acute MI.17 However, recent studies argued against the
transdifferentiation potential of MSCs and proposed that the main mechanism of MSCs on
cardiovascular disease may be paracrine action.15, 18–22 Accordingly, in this study, we
designed experiments to elucidate the mechanism of BM-derived MSCs (BM-MSCs) in
myocardial regeneration or repair.
Furthermore, we have attempted to treat diabetic peripheral neuropathy with BM-MSCs.
Although diabetic neuropathy is the most common complication of diabetes, no effective
therapy has been developed.23 Diabetic neuropathy is pathophysiologically associated with
destruction of the vasa nervorum and loss of myelinated neurons.24 Recently we have
reported that endothelial progenitor cells and BM-derived mononuclear cells exert favorable
therapeutic effects on diabetic neuropathy through their angiogenic and neurotrophic
effects.24 Therefore, we sought to utilize MSCs for treating diabetic peripheral neuropathy
based on the angiogenic effects of MSCs.
On the other hand, concerns have been raised about the safety of MSCs for clinical use, with
studies reporting the potential risk of in vitro expanded MSCs to develop tumors upon
transplantation. Human MSCs derived from adipose tissues became immortalized and
spontaneously transformed after long-term culture, possibly due to augmented chromosome
instability associated with dysregulation of telomere activity and cell cycle related genes.25
Mice injected with these MSCs developed tumors in multiple organs. Similarly, mouse BM-
MSCs can become transformed after long-term culture and induce tumors in mice.26–28
Chromosome instability, upregulated c-Myc expression and elevated telomerase activity
were suggested as contributing factors for acquiring malignancy in mouse BM-MSCs. In
addition, the finding that a subpopulation of BM cells recruited to the stomach undergoing
chronic infection became malignant and contributed to gastric cancer over time also
suggests a tendency of BM-MSCs to be cancerous under certain conditions.29 In contrast,
Bernardo et al reported that human BM-derived MSCs do not exhibit spontaneous
transformation after long term in vitro expansion, making this issue controversial.30
However, it was not reported whether non-manipulated short-term cultured MSCs can
acquire severe chromosomal abnormality and induce tumors in vivo.
In this study, using short-term cultured unmodified mouse BM-MSCs, we aimed to treat
experimental diabetic neuropathy and MI. During 4–8 weeks of follow-up, rapidly growing
tumors were observed in both models. Histopathologic studies revealed that these tumors
were primitive sarcoma, and the BM-MSCs had chromosomal abnormalities even at early
Jeong et al. Page 2
Circ Res. Author manuscript; available in PMC 2011 June 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
passages. This is the first study showing malignant tumor formation in the heart following
implantation of any adult stem cells.
Methods
An expanded Methods section is available in the Online Data Supplement at
http://circres.ahajournlas.org.
Mouse bone marrow mononuclear cells were isolated from the femur and tibia of 8 week-
old, male C57/BL mice by density gradient centrifugation. Adherent cells were cultured on
10 cm plastic dishes in complete media (CM) consisting of Dulbecco’s modified Eagle’s
Media -glutamine. Diabetes was induced in 8 week-old, male C57/BL mice by injection of
streptozotocin (150 mg/kg in 0.9% saline). One million (1×106) MSCs were transplanted
into limb of the mice via bilateral intramuscular injection. Acute myocardial infarction was
induced by ligation of the left anterior descending coronary artery of mice. One hundred
thousand (1 × 105) cultured MSCs were injected into the peri-infarct areas and apex. The
sciatic nerves and hearts were stained with either hematoxylin and eosin (H & E) or
antibodies against desmin and α-smooth muscle actin (αSMA). Flow cytometry was
performed by staining with phycoerythrin (PE)-conjugated antibodies against CD44, CD29,
c-kit (CD117), CD31, and CD34. Chromosome analysis was performed at the Cytogenetics
Core of the Dana Farber Harvard Cancer Center. Fifty cells were scored by determining the
number of acrocentric chromosomes, fused chromosomes, chromosome fragments, and ring
chromosomes.
Results
We locally injected cultured MSCs into the hindlimb muscles for treating diabetic
neuropathy. In a first series of the study (n = 10), we used MSCs at passages P3 to P4. In
this experiment, seven mice were sacrificed at 2 and 4 weeks for histologic analysis as
scheduled. Another three mice, due to be sacrificed at 8 weeks, died at 5 weeks. We believe
that high blood glucose might have been responsible for the death of these mice, as diabetic
control mice which did not receive MSCs sometimes died as well. In a second series of
experiments, we injected MSCs at P4–P6 in the same animal model (n = 10). According to
the study design, seven mice were sacrificed at 2 and 4 weeks for histologic examination.
The remaining three mice were scheduled to be sacrificed at 8 weeks; however, one mouse
died at 5 weeks and two mice developed rapidly growing tumors in both hindlimbs between
5 and 8 weeks. These mice were sacrificed at 8 weeks and the tumors were harvested. In
both series of experiments, we could not observe tumors by gross examination by 4 weeks.
Grossly, the tumors protruded visibly and were huge enough to cripple the hindlimbs
(Figure 1A). The tumor covered the entire hindlimb which received the MSCs. Gross
examination of the removed tumors demonstrated soft-flesh consistency, slippery surface
and multiple sites of necrosis (Figure 1A and 1B). Microscopic examination following H &
E staining revealed fascicular arrangement of pleomorphic spindle cells, which is typical for
myoma or sarcoma, and some areas of geographic necrosis due to rapid growth (Figure 1C).
The tumor cells showed hypercelluarity, nuclear hyperchromatism, pleomorphic nucleoli,
cytologic atypia (Figure 1D), and increased mitotic figures, indicative of malignant sarcoma
(Figure 1E and 1F). To more precisely determine the nature of the tumors, we performed
immunostaining with anti-desmin and anti-αSMA antibodies. The tumors were not stained
for desmin but stained for αSMA, indicating that the tumors originated from smooth muscle
cells (Figure 1G).
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To further confirm the causal relationship of tumor and MSCs, we injected the same line of
MSCs at P6 to P8 into the diabetic neuropathy model (n = 15). In this series, 14 mice
developed tumors at earlier time points (3–4 weeks) than in the second series of
experiments. Only one mouse was free from gross tumor until 4 weeks. Together, tumors
developed in 16 out of 35 diabetic mice (46%) in three independent series of cell
transplantation experiments for diabetic neuropathy (Table 1). There was a trend that later
passage MSCs induced tumors earlier and more frequently compared to earlier passage
MSCs.
In another experiment, we sought to treat experimental MI with these MSCs. We used non-
diabetic mice as an MI model to circumvent the effects of diabetes on tumor formation. We
injected the same line of MSCs (1 × 105) at P6 to P10 into the peri-infarct area immediately
after creation of MI (n = 10). To monitor the development of tumors, we performed
echocardiography every week. Until 6 weeks, we were not able to find any distinct masses;
however, one mouse died at seven weeks. During necropsy, infiltrating tumor was observed
which was extended into the posterior part of the heart (Figure 2). As this finding suggests
that our echocardiographic resolution may not clearly detect the occurrence of tumors, we
sacrificed all the mice and performed necropsy. Gross and microscopic examinations of
these mice revealed that three out of 10 mice (30%) had tumors at 7 weeks (Table 1).
By gross examination, tumors showed an invasive nature: tumors invaded internally into
myocardium and externally into the pericardium and further into the lung and the chest wall
(Figure 2A, 2B, and 2C). Microscopic examination of H & E stained cardiac tissues clearly
demonstrated infiltrative growth of hypercellular tumors occupying one third of the
myocardial wall and invading externally into the pericardium and the chest wall. The tumors
showed fascicular arrangement of atypical spindle cells having pleomorphic,
hyperchromatic nuclei and eosinophilic cytoplasm (Figure 2D). Immunohistochemistry
showed that the tumors were positive for αSMA (Figure 2E and 2F). These tumors were
identified as the same type of tumors that were observed in the diabetic neuropathy model.
Based on these gross and microscopic features, the tumors were diagnosed as spindle cell
sarcoma with myogenic differentiation, which is a primitive and malignant type of sarcoma.
We wondered whether these MSCs had any phenotypic distinction from normal MSCs. We
therefore investigated the cell biologic characteristics of these tumor-forming MSCs using
FACS and chromosome analyses. The MSCs at P4 showed typical morphology of spindle
cells (Figure 3A). FACS analysis demonstrated that 99% of these cells expressed typical
MSC markers such as CD44 and CD29, and did not exhibit hematopoietic lineage markers
such as c-kit, flk1, or CD34 (Figure 3B). We used BM mononuclear cells for culturing
MSCs at the start, and there are usually contaminating hematopoietic lineage cells up to
passage 2. Thus passage 3 cells are regarded as the first clone of MSCs in our culture
method. Chromosome analysis of these tumor-forming MSCs showed multiple
chromosomal abnormalities including fusion, fragmentation, and ring formation (Figure 3D,
Table 2). Such chromosome abnormalities were found in both P4 and P8 MSCs. These
findings suggest that tumor-forming MSCs have chromosomal abnormalities without
demonstrating any abnormal morphology or unusual surface epitopes of MSCs.
Discussion
We demonstrate that culture-expanded BM-MSCs possess chromosomal aberrations even at
passage 4 of culture, and transplantation of these cells induces malignant tumors in mouse
diabetic neuropathy and MI models. P4 is equivalent to passage 2 as a MSC line and can be
usually obtained within 4 weeks of culture. This is often the minimum number of passages
required to obtain enough cells to be used in pre-clinical or clinical studies. Clinical trials
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are underway using human MSCs for treating ischemic heart diseases.31 Since the heart is
an organ which only rarely develops malignant tumors,32 the present study suggests the
aggressiveness of anomalous MSCs and prompts more careful attention to the potential side
effects of cell therapy using MSCs in humans.
MSCs have been widely used for regenerating bone, cartilage, skeletal muscle and even
neural tissues in patients as well as in animal models due to their multipotency.33, 34
However, tumor formation has not been reported in animal or human studies to date with
adult stem cells including MSCs that were passaged for short-term periods without genetic
modification. Recently, spontaneous transformation of BM-derived rat MSCs, with
abnormalities in cell morphology, cell proliferation rate, surface marker expression, and
chromosome number, was found at passages as early as passage 3, whereas no tumors were
observed in any organs in nude mice after intravenous injection of these transformed
MSCs.35 There was a report of sarcoma formation by cultured mouse MSCs that had been
genetically modified using transposons.26 On the other hand, there have been two reports
that late-passaged mouse and human MSCs (P16 to P20) developed chromosomal
abnormalities and underwent spontaneous cancerous transformation in vitro and in
vivo.25, 27 The mechanism by which MSCs are transformed into malignant cells is known to
be related to chromosomal abnormalities, including structural and numerical aberrations,
and increases with higher passage numbers.27 Miura et al intentionally induced spontaneous
immortalization after numerous passages (P29 – P54) and demonstrated a contribution of
these transformed cells to fibrosarcoma formation in vivo. Rubio et al showed that although
MSCs can be managed safely during the standard ex vivo expansion period (6–8 weeks),
human MSCs can undergo spontaneous transformation following long-term in vitro culture
(4–5 months), and the transformed cells lead to formation of tumors in mice.25 We used
‘unmodified’ MSCs at early passages to avoid potential chromosomal abnormalities that
result from long-term culture. However, these MSCs developed chromosomal abnormalities
and induced malignant tumors when injected in vivo, although the cells display conventional
morphology and surface marker characteristics. The accelerated rate of tumor formation by
P6–P10 MSCs compared to P4–P6 MSCs, suggest that cumulative abnormalities through
ex-vivo culture expansion is likely to promote tumorigenesis in vivo. Studies including ours
suggested that sarcoma could originate from implanted MSCs with altered chromosomal
stability. It is also possible that tumors could be formed by fusion between the MSCs and
resident smooth muscle cells, or that they originate from resident smooth muscle cells
stimulated by the MSCs.27 The possibility of MSC-released cytokines transforming
unidentified host cells into tumor cells is unlikely. As our experimental results indicate
tumors were formed regardless of the host organs (here skeletal muscle or hearts) that were
treated with the same MSC transplantation, albeit not excluded, this possibility appears to be
minimal. Interestingly, opposing effects of MSCs have been reported on surrounding tumor
growth. In general, due to their immunosuppressive actions, MSCs are known to favor
tumor growth.36 However, studies have reported that MSCs may exert antitumorigenic
effects in vitro and in a model of Kaposi’s sarcoma.37, 38
Over the last decade clinical trials have been underway for treating cardiovascular diseases
with various types of adult cells such as endothelial progenitor cells,39 MSCs,40 skeletal
myoblasts,41 and BM mononuclear cells.42 Considering the choice of cells for regenerative
therapy, safety should be considered as a priority in human use. From the standpoint of
tumorigenic potential, more differentiated and uncultured cells may be beneficial; however
high inflammatory and tissue-calcifying activities of uncultured BM cells were reported to
have side effects.43, 44 Multipotency, on the other hand can be associated with tumorigenic
or unwanted cellular differentiation. Therefore, using selected uncultured cells such as
CD34, CD133 or CD31 cells45 or short-term cultured cells may be a safer option for
achieving neovascularization in ischemic cardiovascular diseases.
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This is the first study to report that BM-derived MSCs could possess chromosomal
abnormalities at very early passages of culture and that locally transplanted unmodified
BMderived MSCs could generate malignant tumors in cardiovascular animal models.
Although this study did not use human MSCs, and the chromosomal aberrations are usually
more common in mouse cells than human cells, careful monitoring of chromosome status is
warranted for using culture expanded MSCs for cell therapy.
Novelty and Significance
What Is Known?
• Bone marrow (BM)-derived mesenchymal stem cells (MSCs) hold a great
promise for cell therapy owing to their multipotency and culture-expandability.
• Experimental studies and pilot clinical trials have shown therapeutic benefits of
BM-derived MSCs for ischemic heart disease.
What New Information Does This Article Contribute?
• Unmodified mouse BM-derived MSCs underwent chromosomal abnormalities
even at early passages and induced malignant sarcoma when transplanted into
hearts and hindlimbs.
We sought to apply BM-derived MSCs for treating diabetic neuropathy and acute
myocardial infarction based on their multipotent differentiation potential and paracrine
effects. We isolated mononuclear cells from mouse BM and cultured MSCs using a
conventional manner. During the follow-up of 4–8 weeks after cell transplantation,
growing tumors developed 30~50% of animals. Histopathologic examination revealed
the identity of this tumor as malignant sarcoma and chromosomal analysis showed
multiple chromosomal aberrations of the injected MSCs. This study for the first time
demonstrated that genetically unaltered MSCs even at early passages can undergo
chromosomal abnormalities and generate malignant sarcoma in vivo. This study clearly
highlights the importance of chromosomal status of MSCs and the requirement for close
monitoring thereof when cultured MSCs are used for cell therapy.
Non-standard Abbreviations and Acronyms
BM bone marrow
MI myocardial infarction
MSC mesenchymal stem cells
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Figure 1. Transplanted MSCs generated malignant tumors in a mouse model of diabetic
neuropathy
A, Representative tumors (arrows) in the hindlimbs following BM-MSC transplantation into
hindlimb muscles. B, Serial cross sectional images of the tumors showed multiple sites of
necrosis (arrowheads). C–F, H & E staining showed fascicular arrangement of pleomorphic
spindle cells and area of geographic necrosis (C, an arrowhead). The tumor cells showed
nuclear hyperchromatism, pleomorphism, atypical mitosis (D, double arrows), and increased
mitotic figures (E, arrows) suggesting pleomorphic sarcoma. The tumor cells were elongated
and had abundant pinkish cytoplasms (F). The nuclei were centrally located and blunt ended.
Original magnification ×400. Scale bar, 100 µm. G, Immunohistochemistry with α-smooth
muscle actin showed that tumors were focally positive for α-smooth muscle actin, which is
compatible with the pleomorphic sarcoma with myogenic differentiation. H, Positive control
of α-smooth muscle actin staining (scale bar, 100 µm).
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Figure 2. Transplanted MSCs generated malignant tumors in a mouse model of acute
myocardial infarction
A, Gross necropsy examination after opening the chest wall showed that the tumor mass
(arrow) is extended to pericardial sac and invaded into the lung and chest wall. B and C, The
explanted tumor showed infiltrative growth into the myocardium, pericardium and chest
wall. D, Light microscopic examination after H & E staining revealed infiltrative growth of
hypercellular tumor surrounding almost one third of the heart and protruding out of heart.
The tumor showed fascicular arrangement of atypical spindle cells having pleomorphic,
hyperchromatic nuclei and eosinophilic cytoplasm. Black scale bar 1000 µm. White scale
bar 100 µm. E and F, IHC with α-smooth muscle actin showed the tumor was focally
positive for α-smooth muscle actin staining. Green fluorescence, α-smooth muscle actin;
Blue fluorescence, DAPI for nuclei. G, Positive control of α-smooth muscle actin staining
(scale bar 100 µm).
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Figure 3. Characterization of tumor-forming MSCs
A, MSCs showed typical spindle-shaped morphology. Scale bar 100 µm. B, FACS analysis
showed that 99% of these MSCs expressed CD44 and CD29, but not c-kit, CD31, and
CD34. C, Chromosome analyses of normal MSCs showed normal karyotype, 40 XY. D
Chromosome analyses of tumor-forming MSCs demonstrated multiple chromosomal
abnormalities including fusion, fragmentation, and ring formation.
Jeong et al. Page 13
Circ Res. Author manuscript; available in PMC 2011 June 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Jeong et al. Page 14
Table 1
The incidence of sarcoma formation.
Disease Animal Model Tumor formation
DM neuropathy 16/35 (46%)
Non-DM MI model 3/10 (30%)
Non-DM: non-diabetes
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